I have spent my career to date working in the field of gut health. I have a PhD in gastrointestinal immunology and 18 years’ research experience in gastrointestinal disease in humans and animals. I have a keen interest in intestinal inflammation, particularly mucosal barrier function and novel therapeutics to disrupt inflammatory pathways. In 2019 I became Co-founder and Chief Executive Officer of Ferryx. Ferryx develops next-generation probiotics to improve gut health. I have been responsible for the development of Ferryx's proprietary products since their early stages and have led commercialisation over the last four years. I have led Ferryx through investment rounds, successful grant funding, and into revenue generation via launch of Ferryx's first product, Ferrocalm, in December 2022.